Skip to content

Exelixis EXEL Enterprise value

Enterprise value at other companies

Eli Lilly logo
Eli LillyLLY
$859.77B+10.6%
Pfizer logo
PfizerPFE
$222.4B+9.2%
Summit Therapeutics logo
Summit TherapeuticsSMMT
$14.71B+3.4%
Incyte logo
IncyteINCY
$15.31B+55.9%
Ionis Pharmaceuticals logo
Ionis PharmaceuticalsIONS
$12.92B+175%
BridgeBio Pharma logo
BridgeBio PharmaBBIO
$16.77B+178%

Other financials

Income statement

See full
Revenue$610.8M+10.0%
Gross profit$590.9M+10.2%
Operating income$251.3M+34.5%
Net income$210.5M+31.9%
EPS (diluted)$0.79+43.6%

Balance sheet

See full
Cash & equivalents$226.2M+23.1%
Total debt$169.5M-9.4%
Total equity$1.9B-9.2%
Total assets$2.6B-8.6%

Cash flow

See full
Operating cash flow$251.8M+19.1%
CapEx$1.5M-48.9%
Free cash flow$250.3M+20.1%

Valuation

See full
Market cap$13.05B+10.1%
P/E15.7×-2.8×
P/S5.5×+0.3×

Profitability

See full
Gross margin96.4%-0.3pp
Operating margin39.4%+6.3pp
Net margin35.1%+7.1pp
FCF margin38.6%+2.9pp

Returns & leverage

See full
Return on equity41%+10.8pp
Debt / equity0.1×0.0×
Current ratio3.3×-0.2×

Where this comes from

Calculated from Exelixis’s reported figures.

The official record: Exelixis’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →

Ask your AI about Exelixis's enterprise value.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Exelixis's enterprise value?
Exelixis (EXEL) reported enterprise value of $11.24B in Q1 2026.
How has Exelixis's enterprise value changed year-over-year?
Exelixis's enterprise value increased by 9.5% year-over-year, from $10.26B to $11.24B.
What is the long-term trend for Exelixis's enterprise value?
Over 5 years (2020 to 2025), Exelixis's enterprise value has grown at a 9.8% compound annual growth rate (CAGR), from $6.76B to $10.81B.
What does enterprise value mean?
What it would cost to buy the entire business, debt included and cash netted out.
How do you interpret enterprise value?
The capital-structure-neutral valuation base — used in EV/EBITDA and EV/Sales to compare companies with different leverage on a like-for-like footing.
How does enterprise value compare across companies?
Comparable across non-financial companies via the EV multiples it feeds; not used for banks and insurers.